These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18064652)

  • 1. Skeletal toxicities of treatment in children with cancer.
    Kaste SC
    Pediatr Blood Cancer; 2008 Feb; 50(2 Suppl):469-73; discussion 486. PubMed ID: 18064652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature.
    Wasilewski-Masker K; Kaste SC; Hudson MM; Esiashvili N; Mattano LA; Meacham LR
    Pediatrics; 2008 Mar; 121(3):e705-13. PubMed ID: 18310191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis in children and adolescents.
    Bianchi ML
    Bone; 2007 Oct; 41(4):486-95. PubMed ID: 17706477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the treatment for childhood solid tumors associated with lower bone mass than that for leukemia and Hodgkin disease?
    Muszynska-Roslan K; Konstantynowicz J; Panasiuk A; Krawczuk-Rybak M
    Pediatr Hematol Oncol; 2009 Jan; 26(1):36-47. PubMed ID: 19206007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy.
    Sala A; Mattano LA; Barr RD
    Eur J Cancer; 2007 Mar; 43(4):683-9. PubMed ID: 17169552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis in children with cancer.
    van der Sluis IM; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2008 Feb; 50(2 Suppl):474-8; discussion 486. PubMed ID: 18064660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of genistein aglycone on the development of osteonecrosis of the femoral head and secondary osteoporosis induced by methylprednisolone in rats.
    Bitto A; Polito F; Burnett B; Levy R; Di Stefano V; Armbruster MA; Marini H; Minutoli L; Altavilla D; Squadrito F
    J Endocrinol; 2009 Jun; 201(3):321-8. PubMed ID: 19332450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer chemotherapy-induced osteoporosis: How common is it among Saudi Arabian cancer survivors.
    Al Amri A; Sadat-Ali M
    Indian J Cancer; 2009; 46(4):331-4. PubMed ID: 19749464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy.
    Selimoglu MA; Ertekin V; Doneray H; Yildirim M
    J Clin Gastroenterol; 2008 Feb; 42(2):194-8. PubMed ID: 18209591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA; Galvão DA; Davies R; La Bianca S; Joseph D; Davidson A; Prince R
    BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucorticoids and bone: some general remarks and some special observations in pediatric patients.
    Bianchi ML
    Calcif Tissue Int; 2002 May; 70(5):384-90. PubMed ID: 11960203
    [No Abstract]   [Full Text] [Related]  

  • 12. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
    Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
    Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
    La Vignera S; Vicari E; Tumino S; Ciotta L; Condorelli R; Vicari LO; Calogero AE
    Minerva Ginecol; 2008 Dec; 60(6):475-84. PubMed ID: 18981975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences in the prevalence and severity of bone disease in thalassaemia.
    Kyriakou A; Savva SC; Savvides I; Pangalou E; Ioannou YS; Christou S; Skordis N
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():116-22. PubMed ID: 19337164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
    Book C; Karlsson M; Akesson K; Jacobsson L
    Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of abnormal bone density of pediatric patients prior to blood or marrow transplant.
    Klopfenstein KJ; Clayton J; Rosselet R; Kerlin B; Termuhlen A; Gross T
    Pediatr Blood Cancer; 2009 Oct; 53(4):675-7. PubMed ID: 19533650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I; Vignau J; Collier F; Cortet B
    Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.
    Ruan XY; Jin FY; Liu YL; Peng ZL; Sun YG
    Chin Med J (Engl); 2008 Jul; 121(13):1155-8. PubMed ID: 18710630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis treatments and adverse events.
    Solomon DH; Rekedal L; Cadarette SM
    Curr Opin Rheumatol; 2009 Jul; 21(4):363-8. PubMed ID: 19412101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.